Babafemi O Taiwo1, Lu Zheng2, Andrei Stefanescu3, Amesika Nyaku4, Baiba Bezins1, Carole L Wallis5, Catherine Godfrey6, Paul E Sax7, Edward Acosta8, David Haas9, Kimberly Y Smith10, Beverly Sha11, Cornelius Van Dam12, Roy M Gulick13. 1. Division of Infectious Diseases and Center for Global Health, Northwestern University, Chicago, Illinois. 2. Department of Biostatistics. 3. Statistical Data Management Center, Harvard T H Chan School of Public Health, Boston, Massachusetts. 4. Division of Infectious Diseases, Rutgers University, New Brunswick, New Jersey. 5. BARC South Africa and Lancet Laboratories, Johannesburg, South Africa. 6. Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryl. 7. Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 8. Department of Pharmacology and Toxicology, University of Alabama, Birmingham. 9. Department of Medicine, Vanderbilt University, Nashville, Tennessee. 10. ViiV Healthcare, Research Triangle Park, North Carolina. 11. Division of Infectious Diseases, Rush University, Chicago, Illinois. 12. Regional Center for Infectious Diseases, Cone Health, Greensboro, North Carolina. 13. Division of Infectious Diseases, Weill Cornell Medicine, New York, New York.
Abstract
Background: Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. Methods: A5353 is a phase 2, single-arm, pilot study of once-daily dolutegravir (50 mg) plus lamivudine (300 mg) in treatment-naive participants with HIV-1 RNA ≥1000 and <500000 copies/mL. Exclusion criteria included active hepatitis B or major protease, reverse transcriptase, or integrase resistance. The primary efficacy measure was the proportion with HIV-1 RNA <50 copies/mL (FDA [US Food and Drug Administration] Snapshot) at week 24. Virologic failure (VF) was confirmed HIV-1 RNA >400 copies/mL at week 16/20 or >200 copies/mL at or after week 24. Dolutegravir levels and drug resistance testing were performed at VF. Results: One hundred and twenty participants (87% male, median age 30 years, 37 (31%) HIV-1 RNA >100000 copies/mL) initiated study treatment. Median entry HIV-1 RNA and CD4 count were 4.61 log10 copies/mL and 387 cells/mm3. Virologic efficacy at week 24 was 108/120 (90%, confidence interval [83%, 95%]), with comparable results in the >100000 copies/mL and ≤100000 copies/mL strata, that is, 89% (75%, 97%) and 90% (82%, 96%), respectively. Three participants with VF, had undetected plasma dolutegravir at ≥1 time points; the M184V and R263R/K mutations developed in 1 participant. Two participants experienced grade 3 possible/probable treatment-related adverse events; none discontinued treatment due to adverse events. Conclusions: Dolutegravir plus lamivudine demonstrated efficacy in individuals with pretreatment HIV-1 RNA up to 500000 copies/mL in this pilot trial, but a participant developed resistance mutations. Clinical Trials Registration: NCT02582684.
Background: Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. Methods: A5353 is a phase 2, single-arm, pilot study of once-daily dolutegravir (50 mg) plus lamivudine (300 mg) in treatment-naive participants with HIV-1 RNA ≥1000 and <500000 copies/mL. Exclusion criteria included active hepatitis B or major protease, reverse transcriptase, or integrase resistance. The primary efficacy measure was the proportion with HIV-1 RNA <50 copies/mL (FDA [US Food and Drug Administration] Snapshot) at week 24. Virologic failure (VF) was confirmed HIV-1 RNA >400 copies/mL at week 16/20 or >200 copies/mL at or after week 24. Dolutegravir levels and drug resistance testing were performed at VF. Results: One hundred and twenty participants (87% male, median age 30 years, 37 (31%) HIV-1 RNA >100000 copies/mL) initiated study treatment. Median entry HIV-1 RNA and CD4 count were 4.61 log10 copies/mL and 387 cells/mm3. Virologic efficacy at week 24 was 108/120 (90%, confidence interval [83%, 95%]), with comparable results in the >100000 copies/mL and ≤100000 copies/mL strata, that is, 89% (75%, 97%) and 90% (82%, 96%), respectively. Three participants with VF, had undetected plasma dolutegravir at ≥1 time points; the M184V and R263R/K mutations developed in 1 participant. Two participants experienced grade 3 possible/probable treatment-related adverse events; none discontinued treatment due to adverse events. Conclusions: Dolutegravir plus lamivudine demonstrated efficacy in individuals with pretreatment HIV-1 RNA up to 500000 copies/mL in this pilot trial, but a participant developed resistance mutations. Clinical Trials Registration: NCT02582684.
Authors: M Casadellà; P M van Ham; M Noguera-Julian; A van Kessel; C Pou; L M Hofstra; J R Santos; F Garcia; D Struck; I Alexiev; A M Bakken Kran; A I Hoepelman; L G Kostrikis; S Somogyi; K Liitsola; M Linka; C Nielsen; D Otelea; D Paraskevis; M Poljak; E Puchhammer-Stöckl; D Staneková; M Stanojevic; K Van Laethem; S Zidovec Lepej; B Clotet; C A B Boucher; R Paredes; A M J Wensing Journal: J Antimicrob Chemother Date: 2015-07-17 Impact factor: 5.790
Authors: Pedro Cahn; Anton L Pozniak; Horacio Mingrone; Andrey Shuldyakov; Carlos Brites; Jaime F Andrade-Villanueva; Gary Richmond; Carlos Beltran Buendia; Jan Fourie; Moti Ramgopal; Debbie Hagins; Franco Felizarta; Jose Madruga; Tania Reuter; Tamara Newman; Catherine B Small; John Lombaard; Beatriz Grinsztejn; David Dorey; Mark Underwood; Sandy Griffith; Sherene Min Journal: Lancet Date: 2013-07-03 Impact factor: 79.321
Authors: Sherene Min; Louis Sloan; Edwin DeJesus; Trevor Hawkins; Lewis McCurdy; Ivy Song; Richard Stroder; Shuguang Chen; Mark Underwood; Tamio Fujiwara; Stephen Piscitelli; Jay Lalezari Journal: AIDS Date: 2011-09-10 Impact factor: 4.177
Authors: Nicolas A Margot; Rebecca M Hluhanich; Gregg S Jones; Kristen N Andreatta; Manuel Tsiang; Damian J McColl; Kirsten L White; Michael D Miller Journal: Antiviral Res Date: 2011-12-16 Impact factor: 5.970
Authors: Katherine J Lepik; P Richard Harrigan; Benita Yip; Lu Wang; Marjorie A Robbins; Wendy W Zhang; Junine Toy; Linda Akagi; Viviane D Lima; Silvia Guillemi; Julio S G Montaner; Rolando Barrios Journal: AIDS Date: 2017-06-19 Impact factor: 4.177
Authors: Annemarie M Wensing; Vincent Calvez; Huldrych F Günthard; Victoria A Johnson; Roger Paredes; Deenan Pillay; Robert W Shafer; Douglas D Richman Journal: Top Antivir Med Date: 2014 Jun-Jul
Authors: Pedro Cahn; María José Rolón; María Inés Figueroa; Ana Gun; Patricia Patterson; Omar Sued Journal: J Int AIDS Soc Date: 2017-05-09 Impact factor: 5.396
Authors: Jason Gillman; Patrick Janulis; Roy Gulick; Carole L Wallis; Baiba Berzins; Roger Bedimo; Kimberly Smith; Michael Aboud; Babafemi Taiwo Journal: J Antimicrob Chemother Date: 2019-08-01 Impact factor: 5.790
Authors: Babafemi O Taiwo; Miguel E Quiñones-Mateu; Kimberly Smith; Lu Zheng; Roy Gulick; Amesika N Nyaku; Paul E Sax; Belinda Ha; Johnstone Kumwenda; Maxine Olefsky; Catherine Godfrey; Carole Wallis Journal: AIDS Res Hum Retroviruses Date: 2020-03-09 Impact factor: 2.205
Authors: Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2018-07-24 Impact factor: 56.272
Authors: Koen K A Van Rompay; Said Hassounah; Brandon F Keele; Jeffrey D Lifson; Amir Ardeshir; Jennifer Watanabe; Hanh Thi Pham; Elena Chertova; Raymond Sowder; Jan Balzarini; Thibault Mesplède; Mark A Wainberg Journal: J Virol Date: 2019-01-04 Impact factor: 5.103